Rheumatoid Arthritis News

IV golimumab, combined with methotrexate, is as efficacious among patients with rheumatoid arthritis who are aged 65 years and older as it is among those younger than 65 years, with a slightly higher incidence of serious infections among the older population, according to findings in Arthritis Research & Therapy.

Among patients with rheumatoid arthritis, there is no substantial difference in the risk for any serious infection, including bacterial infection or herpes zoster, with TNF inhibitors plus methotrexate compared with triple therapy, according to data published in Arthritis Care & Research.

Among patients with rheumatoid arthritis, systemic lupus erythematosus and psoriasis, the presence of hypertension or preeclampsia accounts for approximately 10% to 33% of the excess risk for preterm birth, caesarean delivery and small for gestational age, according to data published in Arthritis Care & Research.

Consistent follow-up visits with the same physician and treatment with subcutaneous or IV drugs are associated with better patient-reported experiences among those with inflammatory arthritis, according to findings published in the Journal of Clinical Rheumatology.

A U.S. District Court judge has ruled in favor of Amgen in its lawsuit against Novartis’ Sandoz, which claimed patent infringement on its biologic etanercept by the biosimilar, etanercept-szzs.

The FDA has approved upadacitinib, a 15-mg, once-daily oral JAK inhibitor, for the treatment of moderate-to-severe rheumatoid arthritis among patients who have had an inadequate response to methotrexate, according to an AbbVie press release.

In a landmark FDA approval, AbbVie’s upadacitinib has won the race to enter the drug market as the third JAK inhibitor approved for the treatment of moderate-to-severe rheumatoid arthritis, with the drug expected to be available in the United States within the month.

ORLANDO — A line of progression from disease susceptibility to overt rheumatoid arthritis could potentially begin with environmental factors in the lungs, as well as the gingiva, according to a presenter at the 2019 Rheumatology Nurses Society Annual Conference.

Medication adherence for patients with rheumatoid arthritis, gout and osteoporosis was heavily influenced by the degree of trust patients had in their physician, as well as medication properties and patient capabilities, according to data published in Arthritis Care & Research.

ORLANDO — Among patients with rheumatoid arthritis, the presence of serum anti-citrullinated protein antibodies with erosive disease is a predictor of high health care use, according to data presented at the 2019 Rheumatology Nurses Society Annual Conference.